Special Issue

Formulation Development for Treatment of Tropical Diseases

Message from the Guest Editors

Many tropical diseases, a term that includes both diseases of poverty, like malaria, and the neglected tropical diseases, like leishmaniasis, Chagas disease, and mycetoma, are in urgent need of new treatments.

Formulation development, aimed at optimizing drug exposure at the biophase, has been a central part of the search for new treatments with varying levels of success. Nanotechnologies masking suboptimal API properties have been the key to treatment advances for visceral leishmaniasis. Another form of this disease, cutaneous leishmaniasis, has focused research on topical formulations. The multi-drug treatments for malaria and tuberculosis, with the demands for patient compliance and adherence, have ensured that coformulations of fixed-dose combinations are to the fore. This Special Issue presents articles describing the performance of novel antimicrobial, antiprotozoal, and anthelmintic formulations and nanomedicines administered by both systemic and local (topical, mucosal, or inhalation) routes, to optimize delivery and efficacy while ensuring minimal side effects.

Guest Editors

Prof. Dr. Eder Lilia Romero

Dr. Katrien Van Bocxlaer

Prof. Dr. Simon Croft

Deadline for manuscript submissions

closed (1 June 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/76135

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

